Blood transcriptomic signature in type-2 biomarker-low severe asthma and asthma control.
Zeng, Xue Qing, Jing Li, Chi-Ming Lu, Jiamiao Yamawaki, Tracy Hsu, Yi-Hsiang Vander Lugt, Bryan Hsu, Hailing Busby, John McDowell, P J
Zeng, Xue
Qing, Jing
Li, Chi-Ming
Lu, Jiamiao
Yamawaki, Tracy
Hsu, Yi-Hsiang
Vander Lugt, Bryan
Hsu, Hailing
Busby, John
McDowell, P J
Citations
Altmetric:
Affiliation
Other Contributors
Publication date
2023-06-12
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Abstract
Background: Patients with type-2 (T2) cytokine-low severe asthma often have persistent symptoms despite suppression of T2 inflammation with corticosteroids.
Objectives: We sought to analyze whole blood transcriptome from 738 samples in T2-biomarker-high/-low patients with severe asthma to relate transcriptomic signatures to T2 biomarkers and asthma symptom scores.
Methods: Bulk RNA-seq data were generated for blood samples (baseline, week 24, week 48) from 301 participants recruited to a randomized clinical trial of corticosteroid optimization in severe asthma. Unsupervised clustering, differential gene expression analysis, and pathway analysis were performed. Patients were grouped by T2-biomarker status and symptoms. Associations between clinical characteristics and differentially expressed genes (DEGs) associated with biomarker and symptom levels were investigated.
Results: Unsupervised clustering identified 2 clusters; cluster 2 patients were blood eosinophil-low/symptom-high and more likely to be receiving oral corticosteroids (OCSs). Differential gene expression analysis of these clusters, with and without stratification for OCSs, identified 2960 and 4162 DEGs, respectively. Six hundred twenty-seven of 2960 genes remained after adjusting for OCSs by subtracting OCS signature genes. Pathway analysis identified dolichyl-diphosphooligosaccharide biosynthesis and assembly of RNA polymerase I complex as significantly enriched pathways. No stable DEGs were associated with high symptoms in T2-biomarker-low patients, but numerous associated with elevated T2 biomarkers, including 15 that were upregulated at all time points irrespective of symptom level.
Conclusions: OCSs have a considerable effect on whole blood transcriptome. Differential gene expression analysis demonstrates a clear T2-biomarker transcriptomic signature, but no signature was found in association with T2-biomarker-low patients, including those with a high symptom burden.
Keywords: Severe asthma; T2-cytokine; T2-low; biomarker; oral corticosteroids; whole blood transcriptome.
Citation
Zeng, X., Qing, J., Li, C. M., Lu, J., Yamawaki, T., Hsu, Y. H., Vander Lugt, B., Hsu, H., Busby, J., McDowell, P. J., Jackson, D. J., Djukanovic, R., Matthews, J. G., Arron, J. R., Bradding, P., Brightling, C. E., Chaudhuri, R., Choy, D. F., Cowan, D., Fowler, S. J., … investigators for the UK MRC Refractory Asthma Stratification Program (RASP-UK) (2023). Blood transcriptomic signature in type-2 biomarker-low severe asthma and asthma control. The Journal of allergy and clinical immunology, S0091-6749(23)00751-0. Advance online publication. https://doi.org/10.1016/j.jaci.2023.05.023
Type
Article